APL-130277
Sponsors
Sumitomo Pharma America, Inc.
Conditions
Motor OFF Episodes Associated With Parkinson's DiseaseOff Episodes of Parkinson DiseaseParkinson DiseaseParkinson Disease, Off EpisodesParkinson's Disease
Phase 2
A Study to Examine APL-130277 in Patients With Parkinson's Disease
CompletedNCT02228590
Start: 2014-08-31End: 2014-11-24Updated: 2020-07-30
A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations OFF Episodes
CompletedNCT03187301
Start: 2017-08-03End: 2017-12-21Updated: 2020-08-10
A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by OFF Episodes
CompletedNCT03292016
Start: 2017-08-22End: 2019-03-05Updated: 2020-08-13
Phase 3
Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
CompletedNCT02469090
Start: 2015-06-18End: 2017-12-11Updated: 2020-07-30
Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease
CompletedNCT02542696
Start: 2015-08-31End: 2022-11-08Updated: 2023-11-22
A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (OFF Episodes)
CompletedNCT03391882
Start: 2018-12-19End: 2021-08-11Updated: 2022-12-16